Get started
Author

Ichidai Tanaka

Observed names: I Tanaka, I. Tanaka, Tanaka Ichidai, Tanaka, Ichidai
Institution: Nagoya University
ORCID: 0000-0002-5517-0598
Observed ORCID: 0000-0002-5517-0598
OpenAlex ID: A5000796870
YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes
2012 · T Mizuno, H Murakami, et al. · Oncogene · 279
Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer
2017 · Delphine Dayde, Ichidai Tanaka, et al. · International Journal of Molecular Sciences · 180
PDF
Regulation of PD-L1 expression by matrix stiffness in lung cancer cells
2017 · Ayako Miyazawa, Satoru Ito, et al. · Biochemical and Biophysical Research Communications · 113
PDF
Role of CPS1 in Cell Growth, Metabolism, and Prognosis in LKB1-Inactivated Lung Adenocarcinoma
2016 · Müge Çeliktaş, Ichidai Tanaka, et al. · JNCI Journal of the National Cancer Institute · 107
PDF
Loss of YAP 1 defines neuroendocrine differentiation of lung tumors
2016 · Takeshi Ito, Daisuke Matsubara, et al. · Cancer Science · 102
PDF
Plasma-derived extracellular vesicle proteins as a source of biomarkers for lung adenocarcinoma
2017 · Jody Vykoukal, Nan Sun, et al. · Oncotarget · 78
PDF
LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade
2013 · I Tanaka, H Osada, et al. · Oncogene · 78
PDF
SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1–Negative Lung Adenocarcinomas
2021 · Ichidai Tanaka, Delphine Dayde, et al. · JNCI Journal of the National Cancer Institute · 65
Convergent signaling in the regulation of connective tissue growth factor in malignant mesothelioma: TGFβ signaling and defects in the Hippo signaling cascade
2012 · Makiko Fujii, Hayao Nakanishi, et al. · Cell Cycle · 53
Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
2022 · Soei Gen, Ichidai Tanaka, et al. · BMC Cancer · 46
PDF
Mutational Activation of the NRF2 Pathway Upregulates Kynureninase Resulting in Tumor Immunosuppression and Poor Outcome in Lung Adenocarcinoma
2022 · Johannes F. Fahrmann, Ichidai Tanaka, et al. · Cancers · 42
PDF
The current issues and future perspective of artificial intelligence for developing new treatment strategy in non-small cell lung cancer: harmonization of molecular cancer biology and artificial intelligence
2021 · Ichidai Tanaka, Taiki Furukawa, et al. · Cancer Cell International · 41
PDF
Plasma-Derived Extracellular Vesicles Convey Protein Signatures That Reflect Pathophysiology in Lung and Pancreatic Adenocarcinomas
2020 · Johannes F. Fahrmann, Xiangying Mao, et al. · Cancers · 34
PDF
eIF 2β, a subunit of translation‐initiation factor EIF 2, is a potential therapeutic target for non‐small cell lung cancer
2018 · Ichidai Tanaka, Mitsuo Sato, et al. · Cancer Science · 33
PDF
Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations
2018 · Ichidai Tanaka, Masahiro Morise, et al. · Lung Cancer · 29
Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non–Small-Cell Lung Cancer Patients With EGFR Mutation
2020 · Ichidai Tanaka, Masahiro Morise, et al. · Clinical Lung Cancer · 27
Artificial intelligence-based personalized survival prediction using clinical and radiomics features in patients with advanced non-small cell lung cancer
2024 · Junji Koyama, Masahiro Morise, et al. · BMC Cancer · 21
RASSF3 downregulation increases malignant phenotypes of non-small cell lung cancer
2013 · Asuki Fukatsu, Futoshi Ishiguro, et al. · Lung Cancer · 18
Activation of Yes-Associated Protein in Low-Grade Meningiomas Is Regulated by Merlin, Cell Density, and Extracellular Matrix Stiffness
2015 · Kuniaki Tanahashi, Atsushi Natsume, et al. · Journal of Neuropathology & Experimental Neurology · 17
Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations
2021 · Ichidai Tanaka, Masahiro Morise · International Journal of Molecular Sciences · 14
PDF
Efficacies of programmed cell death 1 ligand 1 blockade in non-small cell lung cancer patients with acquired resistance to prior programmed cell death 1 inhibitor and development of diabetic ketoacidosis caused by two different etiologies: a retrospective case series
2021 · Azusa Ishi, Ichidai Tanaka, et al. · Endocrine Journal · 14
PDF
CADM 1 associates with Hippo pathway core kinases; membranous co–expression of CADM 1 and LATS 2 in lung tumors predicts good prognosis
2019 · Takeshi Ito, Atsuko Nakamura, et al. · Cancer Science · 14
PDF
Candidate tumor-specific CD8 + T cell subsets identified in the malignant pleural effusion of advanced lung cancer patients by single-cell analysis
2024 · Yusuke Sugita, Daisuke Muraoka, et al. · OncoImmunology · 13
Metabolic barriers in non-small cell lung cancer with LKB1 and/or KEAP1 mutations for immunotherapeutic strategies
2023 · Ichidai Tanaka, Junji Koyama, et al. · Frontiers in Oncology · 12
PDF
Non-invasive early prediction of immune checkpoint inhibitor efficacy in non-small-cell lung cancer patients using on-treatment serum CRP and NLR
2022 · Reiko Matsuzawa, Masahiro Morise, et al. · Journal of Cancer Research and Clinical Oncology · 12
PDF
Works count: 76
Citation count: 1,548
H-index: 18
I10-index: 26
Year
Topic
Type